APA (7th ed.) Citation

Goje, O., Sobel, R., Nyirjesy, P., Goldstein, S. R., Spitzer, M., Faught, B., . . . Sobel, J. D. (2023). Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306. Journal of Women's Health (15409996), 32(2), 178. https://doi.org/10.1089/jwh.2022.0132

Chicago Style (17th ed.) Citation

Goje, Oluwatosin, et al. "Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306." Journal of Women's Health (15409996) 32, no. 2 (2023): 178. https://doi.org/10.1089/jwh.2022.0132.

MLA (9th ed.) Citation

Goje, Oluwatosin, et al. "Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306." Journal of Women's Health (15409996), vol. 32, no. 2, 2023, p. 178, https://doi.org/10.1089/jwh.2022.0132.